Heron Therapeutics (HRTX) Q2 FY26 earnings call: guidance and Q&A

Can management elaborate on confidence in meeting updated debt covenants if a Sinvanti generic launches, and whether generic erosion would resemble Sustol's curve?

Management took a very conservative approach with Hercules on the covenants, modeling an early generic launch. They believe the actual generic launch could be delayed due to manufacturing challenges (sterile process, emulsion, scaling 750k-800k units/year) and reimbursement complexities (J code). This conservative modeling provides comfort regarding covenant compliance.

“The way we looked at Cervantes, again, we took a very conservative approach with how we looked at the generic launch. In reality, there's a number of factors here that are at play. First of all, we don't know when the product does come to market. know that there's some manufacturing challenges with this product as we go through them ourselves. It's a sterile process. It's an emulsion.”

asked by Brandon Fulks · answered by Craig Collard

What is driving Zynrelef's below-expectation performance, and what could a well-capitalized strategic partner do differently?

Zynrelef grew 9% QoQ, but Q2 performance was below expectations, which management attributes to execution and the typical seasonal slowness in the market. They expect a strong recovery in the back half of the year, similar to prior trends. The focus is on converting access into cases and protocols in existing accounts. The question about a strategic partner was not directly addressed.

“You know, on ZENERLEF, the product grew 9% quarter over quarter. You know, as you're aware, in Q1, the market itself was down. And so we expected to recover from that, you know, quite strongly in Q2. We didn't quite get to... to our expectations in the second quarter, and certainly that's on us to rectify.”

asked by Brandon Fulks · answered by Mark Hensley

How would a generic launch by Azure impact existing settlement agreements for Sinvanti with other players?

A generic launch, regardless of who launches it, will have no impact on existing settlement agreements for Sinvanti. Those agreements should not change.

“Regarding Sylvante, whether it launches or doesn't launch, it will have no impact at all on the settlement. So that should not change.”

asked by Serge Bellinger · answered by Craig Collard

Is Heron seeing similar macro volatility impacting surgical volumes and healthcare spending as reported by competitors, affecting Zynrelef?

Management believes they were not as impacted by macro volatility, citing continued progress on P&T wins. They acknowledge slower pull-through on some initiatives but expect these to materialize in the back half of the year. The issue is more about execution and timing of pull-through rather than broad macro impacts on surgical volumes.

“Look, I think we still continue to make progress on P&T wins throughout the quarter. So maybe we weren't as impacted as much by that situation, or at least I didn't hear that much about it in particular. But really, it's just about time. of pull through, you know, and we were a little bit slower on a few things in the quarter than we expected and certainly, you know, hope to see those continue to pull through in the back half of the year.”

asked by Serge Bellinger · answered by Mark Hensley